Analysts have set 12-month price targets for Jazz Pharmaceuticals, revealing an average target of $181.11, a high estimate of ...

Global pharma company Jazz Pharmaceuticals has ended patent claims related to its cannabinoid-based epilepsy drug, Epidiolex.

Jazz Pharma has agreed a $7.2 billion deal to by GW Pharmaceuticals and its pioneering cannabis-derived medicines, headed by childhood epilepsy drug Epidiolex. Nasdaq-listed GW is in line for $220 ...

This breakthrough follows GW Pharmaceuticals' $7.2 billion acquisition, highlighting the potential of cannabis-based epilepsy treatments. Argent BioPharma's CannEpil® is poised to follow a similar ...

Dave Ramsey has made a living dishing out advice on personal finance since the late 80s, but just how much has he managed to put away for himself in the process? Here’s what the pop-finance ...

For instance, GW Pharma stated in February 2024 that ... for the highest revenue-grossing segment in the global cannabis pharmaceuticals market in 2023 and is predicted to grow at the fastest ...

The overall sentiment following Prime Minister Narendra Modi's US visit is of confidence and enthusiasm – a belief that a new ...

Many stock investors think there are plenty of buying opportunities in the UK currently, with quality businesses on sale.

As India prepares for pivotal discussions between Prime Minister Narendra Modi and US President Donald Trump in February 2025 ...

The “Cannabis Pharmaceuticals Market by Product ... become aware of these medicinal benefits. For instance, GW Pharma stated in February 2024 that it was starting a new clinical trial to ...

India is one of the countries hardest hit by climate change-induced extreme weather. What should be our priorities in the ...